Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06869551 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
A Phase 3 study of Juvenile Psoriatic Arthritis, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
- 20
- Study locations
NCT06869551: Recruiting Phase 3 study of Juvenile Psoriatic Arthritis, sponsored by Bristol-Myers Squibb.
NCT06869551 is a Phase 3 study of Juvenile Psoriatic Arthritis that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 60 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06869551, a Phase 3 study of Juvenile Psoriatic Arthritis, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Deucravacitinib
Study Locations (20)
Rio Grande do Sul
- Local Institution - 0033 - Porto Alegre
- LMK Serviços Médicos S/S - Porto Alegre
- Local Institution - 0069 - Xangri-lá
Other
- Local Institution - 0027 - Rio de Janeiro
- Local Institution - 0047 - São Paulo
- Local Institution - 0010 - São Paulo
Ohio
- Local Institution - 0065 - Cincinnati
- Local Institution - 0066 - Cleveland
Paraná
- Local Institution - 0013 - Curitiba
- Local Institution - 0072 - Curitiba
California
- Local Institution - 0038 - Lancaster
Illinois
- Local Institution - 0020 - Chicago
Indiana
- Local Institution - 0023 - Indianapolis
New York
- Local Institution - 0059 - North New Hyde Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-03-13 |
| Est. Completion | 2031-03-04 |
| Phase | Phase 3 |
What NCT06869551 shows while recruiting
NCT06869551 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Juvenile Psoriatic Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06869551 names 20 study sites across 14 states, led by Rio Grande do Sul, Other, Ohio.
Frequently Asked Questions
What is clinical trial NCT06869551 about?
NCT06869551 is a clinical study titled "A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis". The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.
What is the current status of trial NCT06869551?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2025-03-13. Estimated completion is 2031-03-04.
What conditions does trial NCT06869551 study?
This clinical trial studies the following conditions: Juvenile Psoriatic Arthritis.
What interventions are being tested in trial NCT06869551?
The interventions under investigation include: Placebo (OTHER), Deucravacitinib (DRUG).
Who is sponsoring clinical trial NCT06869551?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06869551 being conducted?
This trial has 20 study locations across California, Illinois, Indiana, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Juvenile Psoriatic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06869551's enrollment target sits among peer trials
60 1805th of 2000 higher than 177 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
RECRUITING · Phase 3
-
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI